Dr Reddy’s Laboratories has welcomed the opportunity to “further progress our regulated markets journey in biosimilars,” after striking a licensing deal with Shanghai Henlius Biotech for the exclusive rights to the Chinese firm’s HLX15 proposed biosimilar to Johnson & Johnson’s Darzalex (daratumumab).
Henlius And Reddy’s Shake Hands On $130m Darzalex Biosimilar Deal
Licensing Agreement Covers US And Europe For Proposed Biosimilar To Mega-Blockbuster Daratumumab
Fresh from filing its proposed biosimilar to Perjeta with the US FDA, Henlius has brought in Dr Reddy’s Laboratories as its US and European commercial partner for its proposed biosimilar to Darzalex, which has already succeeded in Phase I trials.
More from Deals
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.